Skip to main content

Table 2 Analysis of the clinical characteristics at baseline and after three month follow-up

From: A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia

Variables

Lifestyle wellness program (n=60)

Standard care (n=66)

p

Baseline

3-month

Baseline

3-month

Weight (kg)

81.1 (14.3)

80.7 (14.1)

84.3 (17.8)

84.7 (17.9)

0.093

BMI (kg/m2)

29.1 (4.7)

28.9 (4.7)

29.9 (5.2)

30.0 (5.2)

0.135

Waist (cm)

101.1 (11.2)

100.5 (11.0)

104.1 (13.6)

104.4 (14.1)

0.149

Systolic BP (mmHg)

115.7 (12.7)

114.1 (12.2)

118.3 (16.1)

115.6 (12.4)

0.655

Diastolic BP (mmHg)

78.1 (9.1)

75.9 (10.3)

78.6 (12.0)

78.8 (10.9)

0.304

Glucose (mg/dl)

96.6 (20.5)

94.3 (13.7)

101.2 (35.6)

96.9 (30.1)

0.497

Total Cholesterol (mg/dl)

197.7 (45.7)

191.7 (41.9)

197.1 (40.2)

194.2 (38.8)

0.513

HDL Cholesterol (mg/dl)

44.2 (13.0)

44.3 (12.6)

47.0 (13.7)

46.4 (11.9)

0.585

LDL Cholesterol (mg/dl)

120.2 (37.7)

115.4 (36.2)

115.7 (33.0)

113.3 (34.4)

0.562

Triglycerides mg/dl)

166.7 (95.6)

164.8 (85.1)

165.6 (102.7)

175.5 (112.9)

0.393

Insulin (μU/ml)

11.3 (10.5)

12.8 (12.5)

13.9 (12.1)

14.5 (10.3)

0.616

HOMA-IR

2.8 (3.1)

3.3 (5.1)

3.5 (3.3)

3.6 (3.2)

0.507

  1. BMI: body mass index; BP: blood pressure; HOMA-IR: Homeostatic Model Assessment.